Bao Yanyan, Gao Yingjie, Koch Egon, Pan Xin, Jin Yahong, Cui Xiaolan
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Phytomedicine. 2015 Apr 15;22(4):504-9. doi: 10.1016/j.phymed.2015.03.004. Epub 2015 Mar 20.
EPs(®) 7630 is a proprietary aqueous-ethanolic extract from roots of Pelargonium sidoides DC and has been demonstrated to dispose among others of antibacterial, antiviral, immunomodulatory, antioxidant, and tissue-protective activity. It is an approved medicinal product in more than 50 countries for the treatment of airway infections such as acute bronchitis, common cold, and sinusitis.
While the pharmacological effects of EPs(®) 7630 have extensively been evaluated in diverse in vitro test systems, the number of publications reporting results from in vivo models is limited.
In the present study antitussive, secretolytic, and anti-inflammatory effects of EPs(®) 7630 were assessed in animal experiments following oral administration at human equivalent doses.
Antitussive effects were evaluated using ammonia- and citric acid-induced models of cough in mice (20, 40, 120 mg/kg) and guinea pigs (10, 20, 45 mg/kg), respectively. For the determination of secretolytic activity tracheobronchial secretion of intraperitoneally injected phenol red was determined in mice, while antiinflammatory action was assessed in an acute bacterial bronchitis model in rats.
A significant and dose-dependent reduction of cough frequency was observed in both cough models, which was accompanied by a prolongation of cough latency time. Similarly, the extract exerted a marked secretolytic activity in mice. Induction of acute bacterial bronchitis caused characteristic histopathological changes in lung tissue adjacent to trachea and bronchi. The degree of these lesions was significantly reduced in rats treated with EPs(®) 7630 at doses of 30 and 60 mg/kg. This protective effect at least partially seems to be mediated by an up-regulation of superoxide dismutase and a subsequent protective effect against oxidative stress as indicated by a reduced serum level of malondialdehyde.
The present data further support the therapeutic use of EPs(®) 7630 in respiratory tract infections and provide a basis for detailed studies on its bioactive constituents as well as their in vivo mode of action.
EPs(®) 7630是一种从香叶天竺葵根中提取的专利水醇提取物，已被证明具有抗菌、抗病毒、免疫调节、抗氧化和组织保护活性等多种作用。它是一种在50多个国家获批用于治疗气道感染（如急性支气管炎、普通感冒和鼻窦炎）的药品。
虽然EPs(®) 7630的药理作用已在多种体外测试系统中得到广泛评估，但报告体内模型结果的出版物数量有限。
在本研究中，以人体等效剂量口服给药后，在动物实验中评估了EPs(®) 7630的镇咳、溶解黏液和抗炎作用。
分别使用氨水和柠檬酸诱导的小鼠（20、40、120 mg/kg）和豚鼠（10、20、45 mg/kg）咳嗽模型评估镇咳作用。为了测定溶解黏液活性，在小鼠中测定腹腔注射酚红后的气管支气管分泌物，而在大鼠急性细菌性支气管炎模型中评估抗炎作用。
在两种咳嗽模型中均观察到咳嗽频率显著且呈剂量依赖性降低，同时伴有咳嗽潜伏期延长。同样，该提取物在小鼠中具有显著的溶解黏液活性。急性细菌性支气管炎的诱导导致气管和支气管附近肺组织出现特征性组织病理学变化。在接受30和60 mg/kg剂量EPs(®) 7630治疗的大鼠中，这些病变的程度显著降低。这种保护作用至少部分似乎是由超氧化物歧化酶的上调介导的，随后对氧化应激具有保护作用，这表现为血清丙二醛水平降低。
本数据进一步支持EPs(®) 7630在呼吸道感染中的治疗应用，并为详细研究其生物活性成分及其体内作用方式提供了依据。
